[go: up one dir, main page]

DK1759702T3 - Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning - Google Patents

Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning

Info

Publication number
DK1759702T3
DK1759702T3 DK04748557T DK04748557T DK1759702T3 DK 1759702 T3 DK1759702 T3 DK 1759702T3 DK 04748557 T DK04748557 T DK 04748557T DK 04748557 T DK04748557 T DK 04748557T DK 1759702 T3 DK1759702 T3 DK 1759702T3
Authority
DK
Denmark
Prior art keywords
solution
preparing
prepared
latanoprost eye
latanoprost
Prior art date
Application number
DK04748557T
Other languages
English (en)
Inventor
Bayardo Arturo Jimenez
Monta O Jose Ruben Tornero
Sanchez Marya Isabel Lopez
Olmos Enrique Cruz
Original Assignee
Bayardo Arturo Jimenez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35450648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1759702(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayardo Arturo Jimenez filed Critical Bayardo Arturo Jimenez
Application granted granted Critical
Publication of DK1759702T3 publication Critical patent/DK1759702T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK04748557T 2004-05-26 2004-05-26 Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning DK1759702T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2004/000034 WO2005115401A1 (es) 2004-05-26 2004-05-26 Un método para preparar una solución oftálmica de latanoprost y solución resultante

Publications (1)

Publication Number Publication Date
DK1759702T3 true DK1759702T3 (da) 2009-04-20

Family

ID=35450648

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04748557T DK1759702T3 (da) 2004-05-26 2004-05-26 Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning

Country Status (12)

Country Link
US (4) US8293789B2 (da)
EP (1) EP1759702B1 (da)
AR (1) AR049113A1 (da)
AT (1) ATE419854T1 (da)
BR (1) BRPI0418866A (da)
DE (1) DE602004018990D1 (da)
DK (1) DK1759702T3 (da)
ES (1) ES2320770T3 (da)
PL (1) PL1759702T3 (da)
PT (1) PT1759702E (da)
SI (1) SI1759702T1 (da)
WO (1) WO2005115401A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609634B2 (en) * 2007-05-16 2013-12-17 Mcneil-Ppc, Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
US9579341B2 (en) 2007-05-16 2017-02-28 Johnson & Johnson Consumer Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
CA2691491A1 (en) * 2007-07-11 2009-01-15 Biocydex Sas Complexes of prostaglandin derivatives and monosubstituted, charged beta-cyclodextrins
MX2010003364A (es) * 2007-10-08 2010-07-06 Lux Biosciences Inc Composiciones oftalmicas que comprenden inhibidores de calcineurina o inhibidores de mtor.
US8455547B2 (en) 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
ITRM20080182A1 (it) 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
US9481856B2 (en) 2008-06-09 2016-11-01 Bausch & Lomb Incorporated Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide
WO2010053487A1 (en) * 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2010089355A1 (en) * 2009-02-04 2010-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
DE102009021372A1 (de) * 2009-05-14 2010-11-18 Ursapharm Arzneimittel Gmbh Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung
WO2010144194A1 (en) * 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
SG187770A1 (en) * 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
DE102011108948A1 (de) * 2011-07-29 2013-01-31 Achim Göpferich Wässrige, kolloidale Lösungen von lipophilen Substanzen,insbesondere Arzneistofflösungen
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
ES2669446B1 (es) * 2016-11-24 2019-03-13 Saiz Manuel Munoz Producto oftálmico
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
GR1009419B (el) * 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
WO2020163528A1 (en) * 2019-02-06 2020-08-13 TearClear Corp. Systems and methods for preservative removal from ophthalmic formulations comprising complexing agents
KR20220044248A (ko) 2019-08-07 2022-04-07 아네이라 파마, 인코포레이티드 탈모의 치료를 위한 방법 및 조성물
JP2023530189A (ja) * 2020-06-21 2023-07-13 アイ.コム メディカル ゲーエムベーハー 高眼圧症および緑内障の治療および予防のためのヒアルロン酸に基づく製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
WO2000038689A1 (fr) * 1998-12-25 2000-07-06 Sucampo, A.G. Compositions de medicament pour traiter l'hypertension oculaire ou le glaucome
JP2003531824A (ja) * 2000-02-01 2003-10-28 ケイマン ケミカル カムパニー,インク. フルプロステノールおよび関連プロスタグランジンF2α類似体の内部1,15−ラクトン、ならびに緑内障および眼高血圧の治療におけるそれらの使用
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
AR035541A1 (es) * 2000-11-13 2004-06-16 Pharmacia Ab Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio

Also Published As

Publication number Publication date
US20110098355A1 (en) 2011-04-28
DE602004018990D1 (de) 2009-02-26
BRPI0418866A (pt) 2007-11-20
AR049113A1 (es) 2006-06-28
EP1759702A1 (en) 2007-03-07
US20080021101A1 (en) 2008-01-24
PL1759702T3 (pl) 2009-06-30
SI1759702T1 (sl) 2009-06-30
ATE419854T1 (de) 2009-01-15
PT1759702E (pt) 2009-04-13
US20110098354A1 (en) 2011-04-28
US8293789B2 (en) 2012-10-23
ES2320770T3 (es) 2009-05-28
US20110105605A1 (en) 2011-05-05
EP1759702B1 (en) 2009-01-07
WO2005115401A1 (es) 2005-12-08

Similar Documents

Publication Publication Date Title
DK1759702T3 (da) Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning
DK1898829T3 (da) Fremgangsmåde til fremstilling af en tandprotesedel og således fremstillet tandprotesedel
DK1748077T3 (da) Fremgangsmåde til fremstilling af protein
FI20050913L (fi) Menetelmä peroksihappojen valmistamiseksi
DK1852430T3 (da) Fremgangsmåde til fremstilling af proanthocyanidinoligomer
DK1896065T3 (da) Fremgangsmåde til fremstilling af vacciner
FR2865631B1 (fr) Lunettes-masque
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1638750T3 (da) Fremgangsmåder til fremstilling af gelplader
DK2058243T4 (da) Fremgangsmåde til fremstilling af drikke
DK1976868T3 (da) Edderkoppesilke-proteiner og fremgangsmåde til fremstilling af edderkoppesilke-proteiner
DK2322511T3 (da) Fremgangsmåde til fremstilling af Telmisartan
DK3281939T3 (da) Kombination, der omfatter et stabilt krystal af 4-oxoquinolin sammensætning
FI20030490L (fi) Menetelmä kuitukoostumuksen valmistamiseksi
MY158073A (en) Process for producing optically active amine derivatives
DK1536685T4 (da) Fremgangsmåde til fremstilling af pasta-ekstruderede sulfonamidsammensætninger
DK2390326T3 (da) Fremgangsmåde til fremstilling af et humant type II-collagen
DK1629960T3 (da) Fremgangsmåde og forme til fremstilling af oftalmiske linser
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1864987T3 (da) Fremgangsmåder til fremstilling af 3-O-beskyttede morphinoner og 3-O-beskyttede morphinon-dienol-carboxylater
DK1727782T3 (da) Fremgangsmåde til fremstilling af aminophenolforbindelser
DK1835816T3 (da) Fremgangsmåde til produktion af proteinhydrolysater
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK1780516T3 (da) Fremgangsmåde til opsætning af et sensornetværk
DK1720852T3 (da) Fremgangsmåde til fremstilling af enantiomerrene 1-substituerede 3-aminoalkoholer